Cargando…

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys

Detalles Bibliográficos
Autores principales:	Liu, J, Li, H, Iampietro, M, Barouch, DH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441349/ http://dx.doi.org/10.1186/1742-4690-9-S2-O48

Ejemplares similares

Adenovirus vectors from various serotypes induce distinct cytokine profiles
por: Teigler, JE, et al.
Publicado: (2012)

Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys
por: Li, H, et al.
Publicado: (2012)

Evidence for Env-V2 sieve effect in breakthrough SIV (MAC251) infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs
por: Sina, S, et al.
Publicado: (2012)

Immune control of an SIV challenge by a heterolgous and direct mucosal vaccination regimen in rhesus monkeys
por: Sun, C, et al.
Publicado: (2012)

Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys
por: Keele, Brandon F., et al.
Publicado: (2017)

Development of replication-competent adenovirus based vaccine vectors
por: Abbink, P, et al.
Publicado: (2012)

Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys
por: Barouch, Dan H., et al.
Publicado: (2012)

Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys
por: Boopathy, Archana V., et al.
Publicado: (2023)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following SIV challenges of vaccinated monkeys
por: Stephenson, KE, et al.
Publicado: (2012)

Virus-specific cellular immune correlates of survival in vaccinated monkeys after SIV challenge
por: Letvin, Norman
Publicado: (2006)

P19-57 LB. Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys
por: Letvin, N, et al.
Publicado: (2009)

Prime-boost regimen potency and efficacy with alphavirus replicons (SIV antigen) in non-human primates challenged with low-dose intra-rectal SIVsmE660
por: Banerjee, K, et al.
Publicado: (2012)

Protection against highly pathogenic SIV by BCG-SIV recombinant priming and attenuated replicating vaccinia-SIV recombinant boosting
por: Zhang, X, et al.
Publicado: (2012)

Sterile Protection against Plasmodium knowlesi in Rhesus Monkeys from a Malaria Vaccine: Comparison of Heterologous Prime Boost Strategies
por: Jiang, George, et al.
Publicado: (2009)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys
por: Whitney, James B., et al.
Publicado: (2014)

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys
por: Kang, Zi Han, et al.
Publicado: (2018)

Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates
por: Luo, Shengxue, et al.
Publicado: (2021)

Full-length HIV-1 immunogens induce greater T lymphocyte responses to conserved epitopes than conserved-region-only HIV-1 immunogens in monkeys
por: Stephenson, KE, et al.
Publicado: (2012)

Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques
por: Vierboom, Michel P. M., et al.
Publicado: (2020)

Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys
por: Liu, Jinyan, et al.
Publicado: (2008)

Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation
por: Liu, Po-Ting, et al.
Publicado: (2020)

Development of a novel simian adenovirus 24 based vaccine vector
por: Abbink, P, et al.
Publicado: (2012)

P19-38. Safety and protective immunity in Rhesus monkeys immunized with replication-defective HIV/SIV vaccine
por: Tung, F, et al.
Publicado: (2009)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
por: Nilsson, C, et al.
Publicado: (2009)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

P04-41. Kinetics of antibody neutralization and viral evolution following envelope vaccination in SIV-infected rhesus monkeys
por: Basavapathruni, A, et al.
Publicado: (2009)

P10-06. Adaptive immune responses elicited by recombinant adenovirus vectors exhibit partial MyD88 dependence
por: Rhee, EG, et al.
Publicado: (2009)

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors
por: Iampietro, M. Justin, et al.
Publicado: (2018)

Correlates of Protection Against SIV(mac251) Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors
por: Tuyishime, Steven, et al.
Publicado: (2018)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

Regulation of synovial cell function by adenovirus vector-mediated gene transduction
por: Tanaka, S, et al.
Publicado: (2003)

Lv4, an activity that restricts nuclear entry of SIV(MAC)/SIV(SM) in human blood cells
por: Pizzato, Massimo, et al.
Publicado: (2013)

P19-37. Replication-defective lymphocytic choriomeningitis virus vectors boost cellular and humoral immunity after DNA or adenovirus vector priming
por: Flatz, LR, et al.
Publicado: (2009)

115 Immune Correlates of Protection in Rhesus Monkeys
por: Barouch, Dan
Publicado: (2014)

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2016)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

A recombinant attenuated Mycobacterium tuberculosis-SIV combination vaccine is safe and immunogenic in immunocompromised, SIV-infected infant macaques
por: Jensen, K, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_93o516s3b4upmril3cafmq78u0